Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 14-Sep-23 9:22 PM View:  | Orbimed Advisors LLC Director | Ikena Oncology, Inc. (IKNA) | 04-Aug-23 | Grant Duplicate | 153,121 | -- | -- | 2% 7.78M to 7.93M | |
| 14-Sep-23 9:17 PM View: | Bonita David P Director | Ikena Oncology, Inc. (IKNA) | 04-Aug-23 | Grant | 153,121 | -- | -- | 2% 7.78M to 7.93M | |
| 24-Jun-22 5:32 PM View: | Bonita David P Director | Ikena Oncology, Inc. (IKNA) | 24-Jun-22 | Purchase | 162,000 | $4.96 | $803,975.00 | (2%) 7.94M to 7.78M | |
| 24-Jun-22 5:39 PM View: | Orbimed Advisors LLC Director | Ikena Oncology, Inc. (IKNA) | 24-Jun-22 | Purchase Duplicate | 162,000 | $4.96 | $803,975.00 | (2%) 7.94M to 7.78M | |
| 24-Jun-22 5:32 PM View: | Bonita David P Director | Ikena Oncology, Inc. (IKNA) | 23-Jun-22 | Purchase | 23,419 | $3.71 | $86,884.50 | (< 1%) 7.64M to 7.61M | |
| 24-Jun-22 5:39 PM View: | Orbimed Advisors LLC Director | Ikena Oncology, Inc. (IKNA) | 23-Jun-22 | Purchase Duplicate | 23,419 | $3.71 | $86,884.50 | (< 1%) 7.64M to 7.61M | |
| 24-Jun-22 5:39 PM View: | Orbimed Advisors LLC Director | Ikena Oncology, Inc. (IKNA) | 22-Jun-22 | Purchase Duplicate | 66,806 | $3.55 | $237,161.00 | (< 1%) 7.66M to 7.59M | |
| 24-Jun-22 5:32 PM View: | Bonita David P Director | Ikena Oncology, Inc. (IKNA) | 22-Jun-22 | Purchase | 66,806 | $3.55 | $237,161.00 | (< 1%) 7.66M to 7.59M | |
| 20-Jan-22 4:30 PM View: | Tessier Maude Chief Business Officer | Ikena Oncology, Inc. (IKNA) | 18-Jan-22 | Option Exercise | 71,786 | $3.54 | $253,800.00 | 249% 28.79K to 100.58K | |
| 12-Jan-22 7:25 PM View: | Zhang Xiaoyan Michelle Chief Scientific Officer | Ikena Oncology, Inc. (IKNA) | 11-Jan-22 | Planned Option Sale | 964 | $12.00 | $11,568.00 | (2%) 45.44K to 44.48K | |
| 12-Jan-22 7:25 PM View: | Zhang Xiaoyan Michelle Chief Scientific Officer | Ikena Oncology, Inc. (IKNA) | 11-Jan-22 | Option Exercise | 964 | $2.15 | $2,068.94 | 2% 44.48K to 45.44K | |
| 12-Jan-22 7:25 PM View: | Zhang Xiaoyan Michelle Chief Scientific Officer | Ikena Oncology, Inc. (IKNA) | 10-Jan-22 | Option Exercise | 36 | $2.15 | $77.26 | < 1% 44.48K to 44.51K | |
| 12-Jan-22 7:25 PM View: | Zhang Xiaoyan Michelle Chief Scientific Officer | Ikena Oncology, Inc. (IKNA) | 10-Jan-22 | Market Option Sale (Planned) | 36 | $12.00 | $432.00 | (< 1%) 44.51K to 44.48K | |
| 14-Dec-21 8:27 PM View: | Atlas Venture Fund Xi, L.P. 10% Owner | Ikena Oncology, Inc. (IKNA) | 14-Dec-21 | Market Sale | 5,959 | $14.00 | $83,426.00 | (< 1%) 2.12M to 2.12M | |
| 14-Dec-21 8:29 PM View: | Formela Jean Francois Director | Ikena Oncology, Inc. (IKNA) | 14-Dec-21 | Market Sale Duplicate | 5,959 | $14.00 | $83,426.00 | (< 1%) 5.02M to 5.02M | |
| 14-Dec-21 8:29 PM View: | Formela Jean Francois Director | Ikena Oncology, Inc. (IKNA) | 13-Dec-21 | Market Sale Duplicate | 8,330 | $14.64 | $121,951.00 | (< 1%) 5.03M to 5.02M | |
| 14-Dec-21 8:27 PM View: | Atlas Venture Fund Xi, L.P. 10% Owner | Ikena Oncology, Inc. (IKNA) | 13-Dec-21 | Market Sale | 8,330 | $14.64 | $121,951.00 | (< 1%) 2.13M to 2.12M | |
| 14-Dec-21 8:29 PM View: | Formela Jean Francois Director | Ikena Oncology, Inc. (IKNA) | 10-Dec-21 | Market Sale Duplicate | 11,989 | $15.03 | $180,195.00 | (< 1%) 5.04M to 5.03M | |
| 14-Dec-21 8:48 PM View: | Zhang Xiaoyan Michelle Chief Scientific Officer | Ikena Oncology, Inc. (IKNA) | 10-Dec-21 | Option Exercise | 1,000 | $2.15 | $2,146.20 | 2% 44.48K to 45.48K | |
| 14-Dec-21 8:48 PM View: | Zhang Xiaoyan Michelle Chief Scientific Officer | Ikena Oncology, Inc. (IKNA) | 10-Dec-21 | Market Option Sale | 1,000 | $14.76 | $14,759.90 | (2%) 45.48K to 44.48K | |
| 14-Dec-21 8:27 PM View: | Atlas Venture Fund Xi, L.P. 10% Owner | Ikena Oncology, Inc. (IKNA) | 10-Dec-21 | Market Sale | 11,989 | $15.03 | $180,195.00 | (< 1%) 2.14M to 2.13M | |
| 01-Apr-21 6:13 PM View: | Orbimed Advisors LLC Director | Ikena Oncology, Inc. (IKNA) | 30-Mar-21 | Conversion | 7,099,800 | -- | -- | 100% 0 to 7.1M | |
| 01-Apr-21 6:16 PM View: | Stampacchia Otello Director | Ikena Oncology, Inc. (IKNA) | 30-Mar-21 | Conversion | 1,799,120 | -- | -- | 400% 450.0K to 2.25M | |
| 01-Apr-21 6:14 PM View: | Bonita David P Director | Ikena Oncology, Inc. (IKNA) | 30-Mar-21 | Purchase Duplicate | 423,400 | $16.00 | $6,774,400.00 | 6% 7.1M to 7.52M | |
| 01-Apr-21 6:14 PM View: | Bonita David P Director | Ikena Oncology, Inc. (IKNA) | 30-Mar-21 | Conversion Duplicate | 7,099,800 | -- | -- | 100% 0 to 7.1M | |
| 01-Apr-21 6:23 PM View: | Formela Jean Francois Director | Ikena Oncology, Inc. (IKNA) | 30-Mar-21 | Conversion Duplicate | 4,750,360 | -- | -- | 2809% 169.1K to 4.92M | |
| 14-Dec-21 8:27 PM View: | Atlas Venture Fund Xi, L.P. 10% Owner | Ikena Oncology, Inc. (IKNA) | 30-Mar-21 | Purchase | 125,000 | $16.00 | $2,000,000.00 | 6% 2.02M to 2.14M | |
| 01-Apr-21 6:16 PM View: | Stampacchia Otello Director | Ikena Oncology, Inc. (IKNA) | 30-Mar-21 | Grant | 450,000 | $16.00 | $7,200,000.00 | 100% 0 to 450.0K | |
| 01-Apr-21 6:16 PM View: | Atlas Venture Fund X, L.P. 10% Owner | Ikena Oncology, Inc. (IKNA) | 30-Mar-21 | Conversion | 4,750,360 | -- | -- | 2809% 169.1K to 4.92M | |
| 01-Apr-21 6:13 PM View: | Orbimed Advisors LLC Director | Ikena Oncology, Inc. (IKNA) | 30-Mar-21 | Purchase | 423,400 | $16.00 | $6,774,400.00 | 6% 7.1M to 7.52M | |
| 14-Dec-21 8:29 PM View: | Formela Jean Francois Director | Ikena Oncology, Inc. (IKNA) | 30-Mar-21 | Purchase Duplicate | 125,000 | $16.00 | $2,000,000.00 | 3% 4.92M to 5.04M |
